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Abstract 
Fabry disease (FD) is an X-linked lysosomal storage disorder characterized by a deficient 
activity of the enzyme α-galactosidase A, resulting in a vasculopathic involvement of 
various organ systems, e.g. cerebral structures. Marked cerebral vasculopathy with 
subsequent white matter lesions (WML) are a frequent finding in FD patients. Recent 
studies discussed an association between cerebral white matter changes and sleep-
related disturbances of breathing, which may lead to excessive daytime sleepiness (EDS). 
A 56-year-old Caucasian female FD patient with EDS was admitted to our sleep 
laboratory. Overnight polysomnography showed a Cheyne-Stokes respiration pattern 
with significant O2 desaturation. MR imaging revealed confluent WML including the brain 
stem, but no renal or cardiac involvement. We then evaluated the clinical data of 49 
genetically proven FD patients (27 males; mean age 43 years) from our FD centre. With a 
frequency of 68%, EDS exceeds the prevalence of other common symptoms of FD 
(angiokeratomas 61%; acroparaesthesia 51%; renal involvement 29%; cardiac 
involvement 27%), and the prevalence of chronic fatigue (48%). EDS was independently 
associated with the physical component summary of the SF-36 data (corrected R2 = 
–0.323, p < 0.001). EDS and age explained a quarter of variance in mental component 
summary (corrected R2 = –0.253, p < 0.001). We conclude that EDS is a common and 
underdiagnosed symptom in FD patients, accompanied by a significant impact on 
quality of life. EDS might be caused by central breathing disorders due to an affection of 
brain regions associated with respiratory control in FD. 
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Introduction 
Fabry disease (FD) is a X chromosome-linked inherited lysosomal storage disorder, 
due to partial or complete deficient activity of the enzyme α-galactosidase A caused by 
different X-chromosomal recessive mutations in the galactosidase gene. The decrease or 
absence of enzyme activity results in progressive accumulation of neutral 
glycosphingolipids in various organ systems, preferentially in the vascular endothelium 
and in smooth muscle cells, leading to microangiopathy, vessel occlusion, and ischemic 
tissue damage. In the first two decades, neuropathic pain, hypohydrosis, gastrointestinal 
symptoms and angiokeratoma are the clinical hallmarks [1]. Lifespan is shortened by late 
complications in adulthood, mainly caused by heart failure, renal dysfunction and 
cerebrovascular involvement (premature strokes and white matter lesions; WML) [2]. 
Clinical symptoms of FD are associated with significant impact on quality of life (QoL). 
The reduction in QoL in FD patients has been reported to be similar to that in AIDS 
patients [3]. 
Chronic fatigue is a frequent and early finding in FD patients with a significant impact 
on QoL. Although a common symptom in patients with chronic renal or cardiac 
dysfunction, chronic fatigue also appears in FD patients in whom renal or cardiac 
involvement has not been manifested [1]. Despite much research, the underlying 
pathophysiology of chronic fatigue still remains unknown. 
Recent studies have demonstrated an association between cerebral white matter 
changes and sleep-disordered breathing, which may contribute to excessive daytime 
sleepiness (EDS) and subjective measures of daytime fatigue [4]. Severe progressive 
cerebral WML are frequent findings in FD and occur from an early age [2]. It may 
therefore be speculated that EDS is a frequent and under-diagnosed feature of FD, often 
falsely regarded as chronic fatigue. 
We present an instructive case of EDS in a FD patient from our sleep laboratory with 
severe leukoaraiosis. To better determine the frequency of daytime sleepiness and its 
impact on QoL in FD, we consecutively evaluated the prevalence of EDS in a 
biochemically and genetically proven group of Fabry patients and assessed possible 
associations with multiple organ involvement. 
Case Report 
A 56-year-old Caucasian female FD patient was admitted to our sleep laboratory because of EDS. 
She had been taking enzyme replacement therapy (ERT) for 4 years. The diagnosis of FD was confirmed 
4 years ago (by measurement of enzyme activity and molecular genotyping), but she had suffered from 
neuropathic pain and hypohidrosis since she was 15. Echocardiograhy, kidney function tests, and 
routine biochemistry showed normal results, excluding severe cardiac or renal involvement. Further 
medical history and neurological examination were normal. Twenty-four-hour blood pressure levels 
were unrevealing (mean systolic/diastolic pressure 109/78 mm/Hg), with a mean arterial pressure of 99 
mm Hg and preserved nocturnal dipping. An EEG was normal, nerve-conduction velocities and extra- 
and transcranial Duplex-ultrasonography showed no pathological findings. 
The patient had a pathological Epworth Sleepiness Scale (ESS) score of 20 (normal <10) and a 
decreased multiple sleep latency test (MSLT) score of 4.6 min (normal >10 min). QoL was measured 
using the SF-36 health-related quality of life survey (http://www.sf36.org). Two summary scores are 
computed to reflect the physical or mental domains of health-related QoL: physical component 
summary (PCS) and mental component summary (MCS). QoL scores were markedly decreased (PCS: 
33; MCS: 40). Polysomnography (overnight
 recording of sleep-wake cycles, electrocardiogram, 
electroencephalogram, electromyogram, oronasal air
 flow, chest wall and abdominal wall effort, and 
pulse oximetry) showed a Cheyne-Stokes respiration pattern characterized by periodic breathing with  
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recurrent episodes of central apneas and hypopneas, alternating with hyperpneas and characteristic 
crescendo-decrescendo
 pattern of tidal volume (fig. 1, upper row). The central apnea/hypopnea index 
was 64/h (pathologic: >10/h) and respiratory arousal index was 46/h (pathologic: ≥5 arousals per total 
sleep time), with repeated oxyhemoglobin desaturations up to 65%. Subsequently, an MRI showed 
confluent hyperintense regions on FLAIR- and T2-weighted MRI sequences, and corresponding 
decreases of signal on T1-weighted images bilaterally in the cerebral white matter, with substantial 
brainstem involvement (fig. 1, lower row). 
Group Study 
After a comprehensive history by interview and searching of patients’ documents, recording of 
clinical data of 49 FD patients (27 males; mean age 43 years; range 16–72 years) were assessed by a 
standardized questionnaire. To determine severity, patients were classified according to the previously 
described Mainz Severity Score Index (MSSI) [5]. The MSSI is then divided into severity bands of mild 
(<20), moderate (20–40) and severe (>40) affliction. Furthermore, sleepiness, fatigue and QoL were 
measured using the ESS, Fatigue Severity Scale, and the SF-36. We compared the SF-36 scores of the 
present study with those of a large (n = 2911) German general population group [6]. 
For between-group comparisons, continuous variables were evaluated using the Student’s t test. 
Correlations between the findings were tested by calculation of Pearson’s correlation coefficient. To 
evaluate predictors of QoL, multiple stepwise regression analyses were conducted using the PCS and the 
MCS of the SF-36-survey as dependent variables. Demographic (age, gender, years of ERT, age of 
diagnosis) and clinical data (number of affected organs, MSSI-scores, and FSS- and ESS-values) were 
tested as independent variables. 
Results 
The average clinical stage of patients was mild to moderate, and male and female 
patients were comparably affected. The MSSI ranged from 0 to 51 (mean 15). 
Acroparaesthesia was present in 51%. Neurological features were also the earliest to 
develop, beginning
 at an average age of 18 years. Cerebrovascular events were reported in 
10% of cases. Cardiac abnormalities could be detected in 27%. Abnormal renal function 
(proteinuria) was present in 29%, but end-stage renal failure with the need of 
hemodialysis was present in only 6% of patients. Dermatological and gastrointestinal 
symptoms of FD were also common and reported by 61 and 41%, respectively. 
However, EDS and fatigue were the most common clinical symptoms. Pathological 
ESS (≥10) and FSS (≥5) scores were established in 68 and 48% of FD patients, 
respectively. Prevalence rates of individual clinical symptoms are shown in fig. 2. 
Patients with pathological daytime sleepiness (mean ESS 14 ± 3) were slightly younger 
(42 ± 12 vs. 45 ± 13 years, p < 0.007) than patients without daytime sleepiness (mean ESS 
7 ± 3), reported a longer total sleep time (7.35 ± 1.08 vs. 6.95 ± 0.85 h/night, p < 0.03), and 
had more difficulties in maintaining sleep (19.3 ± 4.8% vs. 14.4 ± 3.9%, p < 0.005). The 
mean body mass index (BMI) was 27.6 kg/m
2 (±6.0; normal <25 kg/m
2) and did not differ 
between patients with or without pathological daytime sleepiness. Thirty-one percent of 
patients had a history of recurrent snoring, which was within the reported range of 
habitual snorers in the normal population, and 41% of FD patients reported recurrent 
napping during the day. Sixty-two percent of FD patients reported pathological fatigue 
without overlap of sleepiness, and only 11% reported pathological sleepiness without 
overlap of fatigue. Pearson’s correlation analysis indicated a weak association (r = 0.18) 
between subjective fatigue and sleepiness in the total sample. 
No significant correlations were found between clinical (MSSI and subscores, number 
of affected organs) or demographic (age, gender, years of ERT, age of diagnosis) data and  
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ESS or FSS scores. There were no significant differences among patients with or without 
renal or cardiac involvement or stroke with regard to ESS and FSS scores. 
Compared to the general population, both females and males with FD showed 
consistently impaired QoL, as assessed using the SF-36 data (table 1). The only mean 
SF-36 scores above 67 were the role emotional score and the mental health score. In 
summary, the PCS and MCS were significantly decreased (p < 0.01 and p < 0.05, 
respectively), compared to a German reference population (n = 2,911). The PCS 
correlated inversely with the number of affected organs (r = –0.23; p < 0.05), the renal (r = 
–0.34; p < 0.05), neurological (r = –0.32; p < 0.05) and total (r = –0.39; p < 0.05) MSSI 
scores, and with ESS (r = –0.42; p < 0.001) and FSS (r = –0.38; p < 0.01) values. The MCS 
correlated significantly with FSS (r = –0.44; p < 0.05) and ESS (r = –0.42; p < 0.01) values 
and with age (r = –0.31; p < 0.05). On multiple stepwise regression analyses (table 2) ESS, 
age and the total MSSI values were independently associated with the PCS of the SF-36 
data (corrected R
2 = –0.323; p < 0.001), and ESS and age explained a quarter of variance in 
MCS (corrected R
2 = –0.253; p < 0.001). 
Discussion 
The largest group of disorders causing daytime sleepiness consists of sleep-related 
disturbances of breathing, where neuroregulatory mechanisms play a major role in 
pathophysiology [7]. Recent studies demonstrated an association between change in white 
matter grade and measures of central sleep apnea that was consistent with a causal 
pathway in which central sleep apnea contributes to the progression of white matter 
disease [4]. As a structural basis, an affection of brain regions associated with autonomic 
and respiratory control – as they are classically represented in the brain stem – has been 
suggested [8]. 
In patients with FD, cerebral vasculopathy as a result of progressive sphingolipid 
deposits in the vascular endothelium and vascular smooth muscle has been confirmed by 
neuropathologic, neuroradiologic and functional studies, and occurs frequently at a rather 
early age. Accordingly, cerebral WML are frequent findings in cranial MRI of FD patients 
[2]. In a brain-imaging study of 50 FD patients, who had a mean age of 33 years, only 32% 
had no WML [9]. Additionally, early and widespread ultrastructural cerebral changes in 
FD patients have been detected using advanced MRI techniques such as diffusion tensor 
imaging [2, 10]. Central sleep apnea due to cerebral vasculopathy might be the underlying 
pathomechanism of EDS in FD. Although one can only draw limited conclusions from 
one case report, our findings of a FD patient with severe EDS and confluent WML 
including the brain stem, but without renal or cardiac involvement, support this 
hypothesis and suggest that not only are cerebral white matter changes present in FD 
patients, but also that these may be relevant for the initiation of clinical symptoms. 
With a frequency of 68%, EDS exceeds the prevalence of other common symptoms of 
FD in our consecutively investigated patient group. Moreover, EDS significantly impairs 
QoL, independently of cardiac, renal or neurological involvement. Even though recurrent 
acroparesthesia, cerebrovascular events, hemodialysis or cardiac dysfunction could lead to 
some sleep disturbance, this would not explain the high prevalence rate of EDS. 
Additionally, we found no correlation between these symptoms and ESS scores. 
Although chronic fatigue is a frequently reported symptom of patients with FD, this is 
the first study showing a high prevalence of EDS in this patient group. One reason for this 
might be that sleepiness and fatigue are conceptually distinct but pervasively confounded  
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in research, clinical settings, and everyday spoken language. The pathophysiology of 
chronic fatigue remains unknown and many of the postulated etiologies of chronic fatigue 
syndrome affect sleep. Thus, EDS and fatigue have overlapping features, which can lead to 
imprecise diagnostic formulations and subsequent suboptimal intervention and 
management decisions. For example, it has long been known that fatigue, rather than 
sleepiness, is correlated with the experience of insomnia. Even patients with obstructive 
sleep apnea complain of fatigue, tiredness, and lack of energy [11]. Due to the relative 
dichotomy between sleepiness and fatigue and the underemphasis of fatigue as an 
independent consequence of sleep disorders by many health professionals, the specific 
daytime sleepiness features of sleep apnea are often not recognized, leading to 
underreferral for further diagnostic evaluation procedures. This may result in an 
underdiagnosis of sleep disorders, especially when fatigue rather than sleepiness is 
emphasized as the chief complaint. 
Recent studies have indicated that patients with chronic fatigue had a very high 
incidence of previously undiagnosed primary sleep disorder such as sleep 
apnea/hypopnea syndrome [12, 13]. They also had very high rates of self-reported 
insomnia and nonrestorative sleep. Additionally, narcolepsy and chronic fatigue patients 
were found to be similar on psychological adjustment [12]. These data support the 
hypothesis that primary sleep disorders in individuals with chronic fatigue are 
underdiagnosed in primary care settings. Although a significant portion of patients in this 
study reported pathological fatigue without overlap of sleepiness, only 9% reported 
pathological sleepiness without overlap of fatigue. Thus, it is tempting to speculate that a 
substantial part of FD patients suffers from undiagnosed EDS, potentially caused by a 
treatable primary sleep disorder, which confounded the explicit fatigue questionnaire. 
However, this is the first report addressing an association of EDS and FD and, therefore, 
we believe that this symptom may have been considerably underestimated in FD patients. 
Since chronic fatigue syndrome is reported as a common symptom in various chronic 
diseases, such as malignant, infectious, neuromuscular, or rheumatologic disease, and 
since most studies have not explicitly considered a treatable primary sleep disorder when 
evaluating their patients, many of them may suffer from EDS rather than from chronic 
fatigue. Particularly patients with an involvement of the central nervous system, which is 
a frequent finding in many chronic diseases [14, 15], have an increased risk for sleep-
related breathing disorders. However, this assumption remains hypothetic, and formal 
polysomnographic sleep studies are required to examine this issue. 
In conclusion, our results stress that EDS is a common and – in the present literature – 
underdiagnosed symptom in FD patients, accompanied by a significant impact on QoL. 
Further studies with a larger number of patients are needed to verify the frequency of 
EDS in patients with FD. Therefore, continuous polysomnographic recordings of FD 
patients are required, preferably in combination with cerebral MRI. With a view to the 
existing effective therapies of EDS due to nocturnal breathing disorders, and its enormous 
impact on QoL, clinicians should be aware of this symptom as an additional characteristic 
feature in FD patients. 
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Table 1. Health-related quality of life in FD patients compared to a German reference population  
SF-36 subscales and both 
components 
FD patients  German reference 
population* 
p values 
Physical function  64.8±28.2  85.8±22.1  <0.01 
Physical role   47.1±36.3  83.7±31.7  <0.01 
Bodily pain  63.2±27.9  79.0±27.3  <0.01 
General health  59.8±20.3  68.1±20.1  <0.01 
Vitality 42.6±22.5  63.3±18.4  <0.01 
Social functioning  66.3±24.7  88.7±18.4  <0.01 
Emotional role   81.8±34.3  90.6±25.6  <0.06 
Mental health  70.0±22.2  73.9±16.3  <0.29 
Physical composite summary  44.2±9.8  50.2±10.2  <0.01 
Mental composite summary  43.8±10.2  51.5±8.1  <0.048 
* As reported in Bullinger [6] (n = 2,911), measured by the SF-36-survey. 
 
 
Table 2. Predictors of SF-36 physical and mental component scale 
Dependent variable  Covariants  Standardized β  T  Corrected 
R
2 
p value 
Physical component scale  1. ESS  –0.40  –5.0    <0.001 
 2.  Age  –0.34  –3.5    <0.01 
  3. Total MSSI  –0.18  –2.1  –0.323  <0.05 
Mental component scale  1. ESS  –0.54  –7.4    <0.001 
 2.  Age  –0.21  –4.5  –0.253  <0.01 
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Fig. 1. Lower row: T2-weighted (3.0 Tesla; TR 4000/TE 120) sequences of cranial MRI of a FD patient 
show confluent bilateral white matter changes, significantly involving the brainstem (arrows).  
Upper row: Polysomnographic detail of the same patient shows a Cheyne-Stokes respiration 
characterized by oscillation of ventilation between central apnea and hyperpnea with recurring O2 
desaturation. 
 
 
 
Fig. 2. Prevalence of symptoms and organ involvement in 49 FD patients. Prevalence of each symptom 
is expressed as percentage of the total number of patients. Excessive daytime sleepiness was the most 
common clinical symptom. 
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